In response to DNA damage and replication blocks, cells activate pathways that arrest the
cell cycle and induce the transcription of genes that facilitate repair. In mammals, ATM (ataxia …

Light-chain (L-chain) amyloidosis is characterized by deposition of fibrillar aggregates composed
of the N-terminal L-chain variable region (VL) domain of an immunoglobulin, generally …

Traditionally, most drugs have been discovered using phenotypic or target‐based screens.
Subsequently, their indications are often expanded on the basis of clinical observations, …

Revised Manuscript Received November 10, 1994® abstract: Although it is well accepted that
the structure of amyloid fibrils is dominated by some form of antiparallel/?-sheet, there are …

The human proteome is a major source of therapeutic targets. Recent genetic association
analyses of the plasma proteome enable systematic evaluation of the causal consequences of …

We describe here an inhibitor of in vitro fibril formation, hexadecyl-N-methylpiperidinium (HMP)
bromide, which is selective for the Alzheimer's disease peptide Aβ. At 10 μM, its IC 50 for …

Few proteins have the therapeutic potential of antibodies, which can be developed against
a wide variety of targets and genetically or chemically manipulated to further enhance their …

Resistance to chemotherapy targeting microtubules could be partially because of the delay
in chromosome condensation and segregation during mitosis. The Chfr pathway has been …

Connectivity map data and associated methodologies have become a valuable tool in
understanding drug mechanism of action (MOA) and discovering new indications for drugs. …

As a follow up to the antimycobacterial screening exercise and the release of GSKs first
Tres Cantos Antimycobacterial Set (TCAMS-TB), this paper presents the results of a second …